All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Performance comparison

Follistatin 344 vs Somatrogon (Ngenla)

An educational, source-based comparison of Follistatin 344 and Somatrogon (Ngenla) — how each peptide works, what it's researched for, and what to know before going deeper.

Muscle · Myostatin Inhibition
Follistatin 344

Myostatin-binding protein fragment researched for muscle growth.

Mechanism

A naturally occurring glycoprotein that binds and neutralizes myostatin and activin, releasing the natural brake on skeletal muscle growth in preclinical models.

Research areas
  • Muscular dystrophy models
  • Skeletal muscle hypertrophy
  • Age-related sarcopenia (preclinical)
Considerations
  • Off-target effects on activin signaling (reproductive, cardiac) are a concern.
  • Not FDA-approved; banned by WADA.
Full Follistatin 344 profile →
GH Analog · Endocrine
Somatrogon (Ngenla)

Long-acting recombinant human growth hormone for pediatric GH deficiency — weekly dosing.

Mechanism

A long-acting recombinant fusion protein of human growth hormone with three copies of the C-terminal peptide (CTP) of hCG beta-subunit, extending half-life and enabling once-weekly subcutaneous dosing instead of daily.

Research areas
  • Pediatric growth hormone deficiency
Considerations
  • FDA-approved June 2023.
  • Same class warnings as daily GH (intracranial hypertension, glucose effects, scoliosis progression).
  • Injection-site reactions common.
Full Somatrogon (Ngenla) profile →

Follistatin 344 vs Somatrogon (Ngenla) — Key differences

  • Class: Follistatin 344 is classified as Muscle · Myostatin Inhibition, while Somatrogon (Ngenla) is GH Analog · Endocrine.
  • Primary research focus: Follistatin 344muscular dystrophy models; Somatrogon (Ngenla)pediatric growth hormone deficiency.
  • Tag: Muscle vs FDA-Approved · Endocrine.

Related comparisons